etoposide has been researched along with nalidixic acid in 17 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (11.76) | 18.7374 |
1990's | 6 (35.29) | 18.2507 |
2000's | 3 (17.65) | 29.6817 |
2010's | 6 (35.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barrows, LR; Ireland, CM; Kokoshka, JM | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Sumner, AT | 1 |
Cavolina, P; Di Leonardo, A; Maddalena, A | 1 |
Bohr, V; Hanawalt, P; Mansbridge, J | 1 |
Kort, L; Rowley, R | 1 |
Deisher, TA; Harlan, JM; Kaushansky, K | 1 |
Creus, A; Marcos, R; Ribas, G; Xamena, N | 1 |
Creus, A; Marcos, R; Torres, C | 1 |
Cavalcanti, DP; de Souza, W; Fragoso, SP; Goldenberg, S; Motta, MC | 1 |
1 review(s) available for etoposide and nalidixic acid
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
16 other study(ies) available for etoposide and nalidixic acid
Article | Year |
---|---|
Cell-based screen for identification of inhibitors of tubulin polymerization.
Topics: Animals; Brain Neoplasms; Bucladesine; Cell Differentiation; Drug Screening Assays, Antitumor; Formazans; Glioma; Rats; Tubulin; Tumor Cells, Cultured | 1996 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Inhibitors of topoisomerases do not block the passage of human lymphocyte chromosomes through mitosis.
Topics: Amsacrine; Camptothecin; Chromosome Aberrations; Chromosomes, Human; Daunorubicin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Ellipticines; Ethidium; Etoposide; Humans; In Vitro Techniques; Lymphocytes; Mitosis; Mitoxantrone; Nalidixic Acid; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1992 |
Nalidixic acid-resistant V79 cells with reduced DNA topoisomerase II activity and amplification prone phenotype.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Nucleus; Cell Survival; Cricetinae; Cricetulus; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Etoposide; Gene Amplification; Mesocricetus; Nalidixic Acid; Nucleic Acid Hybridization; Phenotype; Sister Chromatid Exchange; Topoisomerase II Inhibitors | 1992 |
Comparative effects of growth inhibitors on DNA replication, DNA repair, and protein synthesis in human epidermal keratinocytes.
Topics: Anthralin; Aphidicolin; Cells, Cultured; Diterpenes; DNA Repair; DNA Replication; Etoposide; Growth Inhibitors; Humans; Keratins; Molecular Weight; Nalidixic Acid; Novobiocin; Protein Biosynthesis; Skin; Skin Diseases; Topoisomerase II Inhibitors | 1986 |
Novobiocin, nalidixic acid, etoposide, and 4'-(9-acridinylamino)methanesulfon-m-anisidide effects on G2 and mitotic Chinese hamster ovary cell progression.
Topics: Amsacrine; Animals; Cell Line; Cell Survival; DNA Damage; Etoposide; Interphase; Metaphase; Mitosis; Nalidixic Acid; Novobiocin; RNA; Topoisomerase II Inhibitors | 1989 |
Inhibitors of topoisomerase II prevent cytokine-induced expression of vascular cell adhesion molecule-1, while augmenting the expression of endothelial leukocyte adhesion molecule-1 on human umbilical vein endothelial cells.
Topics: Base Sequence; Cell Adhesion Molecules; Cells, Cultured; DNA; E-Selectin; Endothelium, Vascular; Etoposide; Gene Expression Regulation; Humans; Molecular Sequence Data; Nalidixic Acid; Novobiocin; Protein Biosynthesis; Protein Kinase C; RNA, Messenger; Topoisomerase II Inhibitors; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 1993 |
Sister-chromatid exchanges (SCE) induction by inhibitors of DNA topoisomerases in cultured human lymphocytes.
Topics: Amsacrine; Camptothecin; Cells, Cultured; Enzyme Inhibitors; Etoposide; Humans; Lymphocytes; Mitomycin; Nalidixic Acid; Sister Chromatid Exchange; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1996 |
Genotoxic activity of four inhibitors of DNA topoisomerases in larval cells of Drosophila melanogaster as measured in the wing spot assay.
Topics: Amsacrine; Animals; Camptothecin; Drosophila melanogaster; Etoposide; Larva; Mutagens; Nalidixic Acid; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1998 |
The effect of topoisomerase II inhibitors on the kinetoplast ultrastructure.
Topics: Animals; DNA Replication; DNA Topoisomerases, Type II; DNA, Kinetoplast; Enzyme Inhibitors; Etoposide; Nalidixic Acid; Novobiocin; Parasitic Sensitivity Tests; Topoisomerase II Inhibitors; Trypanocidal Agents; Trypanosomatina | 2004 |